Literature DB >> 32269898

Advances in protein misfolding, amyloidosis and its correlation with human diseases.

Debanjan Kundu1, Kumari Prerna1, Rahul Chaurasia2, Manoj Kumar Bharty2, Vikash Kumar Dubey1.   

Abstract

Protein aggregation, their mechanisms and trends in the field of neurodegenerative diseases is still far from completely being decoded. It is mainly attributed to the complexity surrounding the interaction between proteins which includes various regulatory mechanisms involved with the presentation of abnormal conditions. Although most proteins are functional in their soluble form, they have also been reported to convert themselves into insoluble aggregates under certain conditions naturally. Misfolded protein forms aggregates which are mostly unwanted by the cellular system and are mostly involved in various pathophysiologies including Alzheimer's, Type II Diabetes mellitus, Kurus's etc. Challenges lie in understanding the complex mechanism of protein misfolding and its correlation with clinical evidence. It is often understood that due to the slowness of the process and its association with ageing, timely intervention with drugs or preventive measures will play an essential role in lowering the rate of dementia causing diseases and associated ailments in the future. Today approximately more than 35 proteins have been identified capable of forming amyloids under defined conditions, and nearly all of them have been associated with disease outcomes. This review incorporates a major understanding from the history of diseases associated with protein misfolding, to the current state of neurodegenerative diseases globally, highlighting challenges in drug development and current state of research in a comprehensive manner in the field of protein misfolding diseases. There is increasing clinical association of protein misfolding with regards to amyloids compelling us to thread questions solved and further helping us design possible solutions by generating a pathway-based research on which future work in this field could be driven. © King Abdulaziz City for Science and Technology 2020.

Entities:  

Keywords:  Aggregation; Amyloidosis; Neurodegenerative diseases; Neuropharmacology; Protein misfolding

Year:  2020        PMID: 32269898      PMCID: PMC7128022          DOI: 10.1007/s13205-020-2166-x

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  146 in total

1.  How type II diabetes-related islet amyloid polypeptide damages lipid bilayers.

Authors:  Chang-Chun Lee; Yen Sun; Huey W Huang
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  Atomic-resolution three-dimensional structure of HET-s(218-289) amyloid fibrils by solid-state NMR spectroscopy.

Authors:  Hélène Van Melckebeke; Christian Wasmer; Adam Lange; Eiso Ab; Antoine Loquet; Anja Böckmann; Beat H Meier
Journal:  J Am Chem Soc       Date:  2010-10-06       Impact factor: 15.419

3.  Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils.

Authors:  Michael T Colvin; Robert Silvers; Qing Zhe Ni; Thach V Can; Ivan Sergeyev; Melanie Rosay; Kevin J Donovan; Brian Michael; Joseph Wall; Sara Linse; Robert G Griffin
Journal:  J Am Chem Soc       Date:  2016-07-14       Impact factor: 15.419

4.  Intermolecular alignment in Y145Stop human prion protein amyloid fibrils probed by solid-state NMR spectroscopy.

Authors:  Jonathan J Helmus; Krystyna Surewicz; Marcin I Apostol; Witold K Surewicz; Christopher P Jaroniec
Journal:  J Am Chem Soc       Date:  2011-08-15       Impact factor: 15.419

Review 5.  Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease.

Authors:  W Sue T Griffin; Robert E Mrak
Journal:  J Leukoc Biol       Date:  2002-08       Impact factor: 4.962

Review 6.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Authors:  Mark S Forman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2004-10       Impact factor: 53.440

Review 7.  Nucleotide salvage deficiencies, DNA damage and neurodegeneration.

Authors:  Michael Fasullo; Lauren Endres
Journal:  Int J Mol Sci       Date:  2015-04-27       Impact factor: 5.923

Review 8.  Intermingled cAMP, cGMP and calcium spatiotemporal dynamics in developing neuronal circuits.

Authors:  Stefania Averaimo; Xavier Nicol
Journal:  Front Cell Neurosci       Date:  2014-11-13       Impact factor: 5.505

9.  Inhibition of HEWL fibril formation by taxifolin: Mechanism of action.

Authors:  Mohsen Mahdavimehr; Ali Akbar Meratan; Maryam Ghobeh; Atiyeh Ghasemi; Ali Akbar Saboury; Mohsen Nemat-Gorgani
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

10.  Good Amyloid, Bad Amyloid-What's the Difference?

Authors:  Roland G Roberts
Journal:  PLoS Biol       Date:  2016-01-26       Impact factor: 8.029

View more
  1 in total

1.  Flavonol glycoside complanatoside A requires FOXO/DAF-16, NRF2/SKN-1, and HSF-1 to improve stress resistances and extend the life span of Caenorhabditis elegans.

Authors:  Lin Tan; Zhuo-Ya Zheng; Lv Huang; Zhong Jin; Su-Lian Li; Gui-Sheng Wu; Huai-Rong Luo
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.